Thermo Fisher Scientific (TMO) Misses Q2 EPS by 28c; lowers guidance

Thermo Fisher Scientific (NYSE: TMO) reported Q2 EPS of $5.15, $0.28 worse than the analyst estimate of $5.43. Revenue for the quarter came in at $10.69 billion versus the consensus estimate of $10.99 billion.

GUIDANCE:

Thermo Fisher Scientific sees FY2023 EPS of $22.28-$22.72, versus the consensus of $23.55. Thermo Fisher Scientific sees FY2023 revenue of $43.4-44 billion, versus the consensus of $45.21 billion.

For earnings history and earnings-related data on Thermo Fisher Scientific (TMO) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Coherent, Inc. (COHR) Tops Q4 EPS by 12c, Offers Guidance
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c